Sanjay Chandrasekhar

Sanjay Chandrasekhar

Auto-generated profile, based on publicly available information

Sanjay Chandrasekhar

University of South Florida, Tampa, Florida

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2019 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
SCSanjay Chandrasekhar
Sanjay Chandrasekhar
MFMichael Fradley
Michael Fradley

9 August 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
DLDae Hyun Lee
Dae Hyun Lee
AKAbhishek Kumar
Abhishek Kumar
TMTurab Mohammed
Turab Mohammed
LPLauren C. Peres
Lauren C. Peres
MAMelissa Alsina
Melissa Alsina
DHDoris K Hansen
Doris K Hansen
Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor T-cell (CAR-T) approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Currently, the incidence of cardiac events associated with ide-cel remains unclear. This was a retrospective single-center observational study of patients treated with ide-cel for RRMM. We included all consecutive patients who received standard-of-care ide-cel treatment at least 1-month follow-up. Baseline clinical risk factors, safety profile, and responses were examined based on the development of a cardiac event. A total of 78 patients were treated with ide-cel, and 11 patients (14.1%) developed cardiac events: heart failure (5.1%), atrial fibrillation (10.3%), nonsustained ventricular tachycardia (3.8%), and cardiovascular death (1.3%). Only 11 of the 78 patients had repeat echocardiogram. Baseline risk factors associated with the development of cardiac events included being female sex and having poor performance status, λ light-chain disease, and advanced Revised International Staging System stage. Baseline cardiac characteristics were not associated with cardiac events. During index hospitalization after CAR-T, higher-grade (≥grade 2) cytokine release syndrome (CRS) and immune cell–associated neurologic syndrome were associated with cardiac events. In multivariable analyses, the hazard ratio for the association of the presence of cardiac events with overall survival (OS) was 2.66 and progression-free survival (PFS) was 1.98. Ide-cel CAR-T for RRMM was associated with similar cardiac events as other types of CAR-T. Worse baseline performance status and higher-grade CRS and neurotoxicity were associated with cardiac events after BCMA-directed CAR-T-cell therapy. Our results suggest that the presence of cardiac events may confer worse PFS or OS; although because of the small sample size, the power to detect an association was limited.

1 October 2019 in Methodist DeBakey Cardiovascular Journal
Verified
Journal Article
Closed access
DLDae Hyun Lee
Dae Hyun Lee
SCSanjay Chandrashekhar
Sanjay Chandrashekhar
MFMichael G. Fradley
Michael G. Fradley
In recent years, dramatic advances in both cancer diagnosis and treatment have led to significantly increased survival rates. As such, cardiovascular toxicities due to oncologic treatments are more frequently identified. Although heart failure and cardiomyopathy have historically been the cardiotoxicities most associated with cancer therapeutics, it is now recognized that all components of the cardiovascular system can be affected. In this review, we discuss electrophysiologic complications of cancer treatments, including atrial and ventricular tachyarrhythmias as well as bradyarrhythmias, and recommend a multidisciplinary approach with both cardiologists and oncologists to provide safe and effective care to these patients.

1 October 2020 in Journal of Invasive Cardiology
Verified
Journal Article
Closed access
HKHouman Khalili
Houman Khalili
PBPriya Bansal
Priya Bansal
HTHaider Al Taii
Haider Al Taii
RMRamez Morcos
Ramez Morcos
MKMichael Kucharik
Michael Kucharik
BMBrijeshwar Maini
Brijeshwar Maini
Transcatheter aortic valve replacement for severe aortic stenosis is an increasingly prevalent treatment in patients who are intermediate or high risk for surgical intervention. This study explores symptomatic relief and quality of life outcomes in a nonagenarian patient population, which has been underrepresented in landmark clinical trials. from Journal of Invasive Cardiology.

4 January 2024 in The Neurohospitalist
Verified
Journal Article
Closed access
VMVivek Mehta
Vivek Mehta
SCSanjay A. Chandrasekhar
Sanjay A. Chandrasekhar
DQDonald L. Quimby
Donald L. Quimby
ABAjay Bhandari
Ajay Bhandari
VMVictoria Mazo
Victoria Mazo
BMBibhu D. Mohanty
Bibhu D. Mohanty
As the population has aged and as aortic valve therapies have evolved, the use of trans-catheter aortic valve replacement (TAVR) has grown dramatically over the past decade. A well-known complication of percutaneous cardiac intervention is embolic phenomena, and TAVR is among the highest risk procedures for clinical and subclinical stroke. As indications for TAVR expand to lower-risk and ultimately younger patients, the long-term consequences of stroke are amplified. Cerebral embolic protection (CEP) devices have taken a on unique preventative role following the Food and Drug Administration approval of the SentinelTM Cerebral Protection System (CPS). More recently, the PROTECTED TAVR study has spurred extensive debate in the neuro-cardiac community. In this review we describe the contemporary literature regarding stroke risk associated with TAVR, the history and role of CEP devices, a PROTECTED TAVR sub-group analysis, and implications for next steps in the field. Lastly, we explore the unique need for CEP in a younger TAVR population, as well as directions for future research.

23 October 2019 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
DLDae Hyun Lee
Dae Hyun Lee
IMIshita Mehra
Ishita Mehra
SCSanjay Chandrasekhar
Sanjay Chandrasekhar
AMAbu-Sayeef Mirza
Abu-Sayeef Mirza
RSRahul Shenoy
Rahul Shenoy
JGJohn Greene
John Greene
Elizabethkingia meningosepticum (E. meningosepticum) is a ubiquitous microorganism previously known as Chryseobacterium meningosepticum. It is emerging as a pathogen responsible for bacteremia in immunocompromised patients such as cancer patients especially those with a history of prolonged hospital stay and frequent instrumentations. A retrospective chart review of all cases over 10 years in Moffitt Cancer Center showed a total of three patients with E. meningosepticum infection. First patient (history of multiple myeloma) underwent endoscopy complicated by aspiration pneumonia and blood culture positive for E. meningosepticum infection. He was treated with ciprofloxacin, cefoxitin, minocycline and metronidazole and was discharged in stable conditions after 10 days. The second patient (current acute myelogenous leukemia) had neutropenic fever in the setting of recent chest port infection. Blood culture from chest port showed E. meningosepticum and was treated with ciprofloxacin, meropenem and minocycline successfully. The third patient (history of esophageal adenocarcinoma and acute myelogenous leukemia) had history of recent pneumonia and cellulitis who came in with recurrent neutropenic fever. Blood culture was positive for E. meningosepticum and was treated with ciprofloxacin and minocycline. However, the infection was complicated by multiorgan failure and required tracheostomy. As these three cases illustrate, E. meningosepticum bacteremia has high 28- day mortality rate (41%). Early identification of the pathogen along with empiric treatment with a fluoroquinolone and/or minocycline is indicated to reduce morbidity and mortality. All authors: No reported disclosures.